Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 3/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.48 |
| ▸ | EGFR | P00533 | 6/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23592000 | 1.00 | TEAD1 (0.48) | TEAD1SLC6A9EGFRDCUN1D1MAOA | |
| SCHEMBL21958800 | 0.93 | SLC6A9 (0.42) | TEAD1SLC6A9EGFRDCUN1D1MAOA | |
| SCHEMBL24781284 | 0.91 | SLC6A9 (0.52) | TEAD1SLC6A9EGFRDCUN1D1MAOA | |
| SCHEMBL21958811 | 0.84 | SLC6A9 (0.46) | TEAD1SLC6A9EGFRDCUN1D1BTK | |
| SCHEMBL21958108 | 0.83 | SLC6A9 (0.56) | TEAD1SLC6A9EGFRDCUN1D1BTK | |
| SCHEMBL21958167 | 0.82 | TEAD1 (0.54) | TEAD1EGFRDCUN1D1BTKUBE2M | |
| SCHEMBL21958241 | 0.80 | TEAD1 (0.50) | TEAD1EGFRDCUN1D1BTKUBE2M | |
| SCHEMBL21958713 | 0.79 | EGFR (0.66) | TEAD1EGFRDCUN1D1BTKGRIN2B | |
| SCHEMBL21958238 | 0.76 | DCUN1D1 (0.53) | TEAD1EGFRDCUN1D1MAOAMAOB | |
| SCHEMBL24780719 | 0.73 | TEAD1 (0.71) | TEAD1EGFRDCUN1D1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885SLC6A9 1701/4885EGFR 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.